Cyplasin Biomedical Ltd.

Location:

9650 - 20 AvenueEdmontonAlbertaT6N 1G1Canada View Map

Revenue:

$2.4 Million

Employees:

12

SIC Codes:

2834, 8731

NAICS Codes:

325412, 541710

Phone:

(780) 469-2975

Fax:

(780) 669-7633
More

Description:

Founded in 2007 and headquartered in Edmonton, Alberta, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company's current goal is to develop and commercialize the anticancer properties of Cyplasin-SC(TM) for skin cancers and melanomas. CBL is publicly traded (CYPL: OTCBB). Cyplasin Biomedical Ltd. was originally incorporated pursuant to the laws of the State of Nevada on May 12, 2004 under the name Glass Wave Enterprises, Inc. Effective February 16, 2007, we changed our name to Cyplasin Biomedical Ltd. and effected a stock split of our authorized, issued and outstanding common stock after we entered into an asset purchase agreement dated February 1, 2007 with Professor Christian Petzelt. The asset purchase agreement saw the company acquiring certain intellectual property rights pertaining to cancer treatments, specifically protein molecules, for potential applications in treating various cancers in exchange for the issuance by our company of shares of our common stock. On April 10, 2007, we entered into an asset purchase agreement with Bioxen Ltd. to acquire other related intellectual property. The closing of the transactions in this asset purchase agreement and the acquisition of the intellectual property occurred on April 10, 2007. The company believes Cyplasin™ will be useful as a therapeutic drug against multiple types of cancer and the first developed application will be Cyplasin-SC™ for the treatment of skin cancer and human melanoma. The Company has initiated preclinical trials for Cyplasin-SC which will demonstrate the efficacy/toxicity profile in animals. These studies will generate the data required for submission to the various regulatory authorities to initiate the next step in product development, which are clinical trials in humans. The finished product will be delivered to the patient either by intravenous injection into the bloodstream or by injection under the skin close to the tumor via a topical microinjection to the tumor mass. Current studies suggest Cyplasin either can cause the death of the whole tumor, or if used in tandem with current surgical procedures will kill any remaining cancer cells which might metastasize or spread to other parts of the body via the blood circulation system, after the tumor has been removed by conventional surgery.

Read More

Competitors

Browse ZoomInfo’s Directories